Acta Oncologica最新文献

Clinico-pathological characteristics and treatment outcome in non-small cell lung cancer in Greenland 2015-2020 - a comparison with the cohort from 2004 to 2010.

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-12-17 DOI: 10.2340/1651-226X.2024.41078

Dorte S Nørøxe, Simone Frandsen, Malene M Clausen, Thomas I Hansen, Uka W Geisler, Alice J Petersen, Seppo W Langer

{"title":"Clinico-pathological characteristics and treatment outcome in non-small cell lung cancer in Greenland 2015-2020 - a comparison with the cohort from 2004 to 2010.","authors":"Dorte S Nørøxe, Simone Frandsen, Malene M Clausen, Thomas I Hansen, Uka W Geisler, Alice J Petersen, Seppo W Langer","doi":"10.2340/1651-226X.2024.41078","DOIUrl":"10.2340/1651-226X.2024.41078","url":null,"abstract":"Background and purpose: Lung cancer is the leading cause of cancer-related mortality in Greenland. Since 2004, medical treatment of lung cancer has been available in Greenland. However, both diagnostic work-up and treatment logistics are hampered by the lack of medical services in smaller settlements, the infrastructure, and extreme arctic weather conditions. Clinico-pathological data and assessment of treatment outcome in lung cancer in Greenland have not been carried out since 2015. This study aims to provide an analysis of Greenlandic patients with non-small cell lung cancer (NSCLC) from 2015 to 2020, compared to the cohort from the 2015 study. We focus on diagnostics, patient and treatment characteristics, and survival rates. Additionally, we include new data on treatment-related factors and diagnostic delays. Patients/material: Clinical-, pathological-, genomic data, tuberculosis status and survival were retrieved from the medical journal.Results: A total of 163 patients were identified. Survival had improved in stage I, III, and IV, and early-stage disease was more often diagnosed as compared to the 2015 cohort. Molecular alterations and PD-L1 expressing tumors were comparable between Greenlandic and Danish patients. Diagnostic delay was a major concern.Interpretation: While NSCLC survival in Greenland has improved over the past decade, significant challenges remain. The trend towards diagnosing more stage IA-IIIA patients and the recent improvements in diagnostic and therapeutic options in Greenland are expected to translate into a better prognosis in the coming years. Addressing diagnostic delays and enhancing treatment options are crucial steps toward improving outcomes for NSCLC patients in Greenland.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"958-964"},"PeriodicalIF":2.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142833417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From trials to practice: Immune checkpoint inhibitor therapy for melanoma patients in Norway.

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-12-17 DOI: 10.2340/1651-226X.2024.41266

Denise Reis Costa, Anna K Winge-Main, Anna Skog, Kaitlyn M Tsuruda, Trude Eid Robsahm, Bettina Kulle Andreassen

{"title":"From trials to practice: Immune checkpoint inhibitor therapy for melanoma patients in Norway.","authors":"Denise Reis Costa, Anna K Winge-Main, Anna Skog, Kaitlyn M Tsuruda, Trude Eid Robsahm, Bettina Kulle Andreassen","doi":"10.2340/1651-226X.2024.41266","DOIUrl":"https://doi.org/10.2340/1651-226X.2024.41266","url":null,"abstract":"Background and purpose: Norway has one of the highest rates of cutaneous melanoma (CM) incidence and mortality globally. Immune checkpoint inhibitor (ICI) therapy for CM was introduced between 2014 and 2017 to improve treatment and patient prognosis, but knowledge about its clinical usage is limited. This study investigates patient's characteristics and treatment patterns in real-world practice compared to clinical trial results.Material and methods: All adult (≥18) CM patients treated with ICI therapy in Norway from 2014 to 2021 were included, utilizing high-coverage data from multiple national registries to describe patients' health, socioeconomic factors, and treatment management, stratified by first ICI therapy. We compared patient and tumour characteristics with findings from five randomized controlled trials (RCTs).Results: Among 2,083 patients receiving ICI therapy, 975 (47%) received nivolumab as their first treatment in the metastatic setting. Patients on combination therapy were younger and had higher education and income levels compared to those on monotherapy. Overall, real-world patients were older and had a higher incidence of brain metastases than those in RCTs. Approximately, 1 in 5 patients would have been excluded from RCTs due to pre-existing autoimmune diseases. Targeted therapy was the most common secondary systemic treatment after first-line PD-1 inhibitors.Interpretation: This study details ICI therapy in Norway, highlighting differences between real-world ICI users and clinical trial participants, raising questions about the effectiveness of this treatment for patients not eligible for trials.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"965-973"},"PeriodicalIF":2.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142845505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imaging-based evaluation of cervical muscle mass and 6-month survival in males with hypopharyngeal carcinoma. 下咽癌男性患者宫颈肌肉质量和 6 个月存活率的影像评估。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-12-17 DOI: 10.2340/1651-226X.2024.40481

Jouni Laurén, Harri Keski-Säntti, Antti Mäkitie, Otso Arponen

{"title":"Imaging-based evaluation of cervical muscle mass and 6-month survival in males with hypopharyngeal carcinoma.","authors":"Jouni Laurén, Harri Keski-Säntti, Antti Mäkitie, Otso Arponen","doi":"10.2340/1651-226X.2024.40481","DOIUrl":"https://doi.org/10.2340/1651-226X.2024.40481","url":null,"abstract":"Background: A significant proportion of newly diagnosed patients with hypopharyngeal carcinoma (HC) are at risk of early death and may not benefit from cancer treatments. Our objective was to assess whether an image-based evaluation of muscle mass could identify patients at risk of impaired survival.Materials and methods: This retrospective study consisted of male patients diagnosed with HC treated at Helsinki University Hospital between 2005 and 2014 (N = 66). Cross-sectional areas of skeletal muscles at the level of the third cervical vertebra (C3) and at the level of the thoracic aortic apex were analyzed using magnetic resonance images and/or computed tomography images. Survival-based cutoff values for low muscle index values were determined using the receiver operating characteristics curves. Kaplan-Meier analyses and Cox proportional hazard models were used to evaluate the associations between the muscle indexes and survival rates.Results: Several muscle indexes were associated with 6-month and 5-year survival. The 6-month survival rate of males with a low sternocleidomastoid muscle index (cutoff 1.73 cm2/m2) was 66%, as opposed to the 97% survival rate for those with an above-the-cutoff muscle index (hazard ratio 13.0 [95% CI 1.5, 116.6]). In a multivariate Cox model adjusted for age, sex, tumor stage, and grade, lower sternocleidomastoid muscle index was significantly associated with decreased 6-month survival.Interpretation: C3-level muscle indexes, particularly the sternocleidomastoid muscle index, are a promising marker in the identification of patients at risk of early mortality and could add confidence in decision-making when choosing between active and palliative care.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"950-957"},"PeriodicalIF":2.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142833418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ESHO 2-85. Hyperthermia as an adjuvant to radiation therapy in the treatment of advanced neck nodes: A randomized multicenter study by the European Society for Hyperthermic Oncology.

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-12-12 DOI: 10.2340/1651-226X.2024.41035

Jens Overgaard, Olav Dahl, Giorgio Arcangeli

{"title":"ESHO 2-85. Hyperthermia as an adjuvant to radiation therapy in the treatment of advanced neck nodes: A randomized multicenter study by the European Society for Hyperthermic Oncology.","authors":"Jens Overgaard, Olav Dahl, Giorgio Arcangeli","doi":"10.2340/1651-226X.2024.41035","DOIUrl":"https://doi.org/10.2340/1651-226X.2024.41035","url":null,"abstract":"Background and purpose: European Society for Hyperthermic Oncology (ESHO) 2-85 is a multicenter randomized trial investigating hyperthermia (HT) as an adjuvant to radiotherapy (RT) in treatment of locally advanced neck nodes. The trial never fulfilled recruitment and was stopped prematurely, and has not previously been published.Patients and methods: Between January 1987 and February 1993, 64 evaluable neck nodes in 54 patients were included. Tumors were stratified according to institution and nodal size and randomly assigned to receive RT alone (2 Gy/fx, 5 fx/wk) to a total dose of 60-70 Gy, including boost, or the same RT followed once weekly by HT (aimed for 43°C for 60 min). The primary endpoint was persistent complete response (local control).Results and interpretation: Sixty-four tumors in 54 patients were evaluable, with a median observation of 17 months. Thirty-four tumors were randomized to RT alone and 30 to RT+HT. Compliance with RT was good. HT was associated with moderate to severe pain and discomfort in 38% of the treatments. In 57% of the heated patients at least one treatment achieved the target temperature. HT did not significantly increase radiation morbidity. The complete response rate was 53% in the RT versus 80% in the RT+HT group, and 3-year persistent local control rate was 32% for RT alone versus 53% for RT+HT; HR: 0.48 [0.23-0.98]. The ESHO 2-85 study demonstrated that addition of a weekly HT treatment to RT of advanced neck nodes significantly enhanced the persistent tumor control. The results substantiate the potential clinical benefit of hyperthermic oncology.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"943-949"},"PeriodicalIF":2.7,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142811782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Delivering improved survivorship care for people affected by advanced or metastatic cancer.

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-12-09 DOI: 10.2340/1651-226X.2024.42197

Julia Lai-Kwon, Sarah Heynemann, Nicolas Hart, Raymond J Chan, Thomas Smith, Andrea L Smith, Larissa Nekhlyudov, Michael Jefford

引用次数: 0

Denosumab combined with radiotherapy as an alternative to surgery for advanced metastatic bone lesions and pathologic fractures: a retrospective case study of 38 patients.

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-12-01 DOI: 10.2340/1651-226X.2024.40977

Mehdy Farhang, Martin Isaksson, Johan Wänman, Richard Löfvenberg, Sead Crnalic

{"title":"Denosumab combined with radiotherapy as an alternative to surgery for advanced metastatic bone lesions and pathologic fractures: a retrospective case study of 38 patients.","authors":"Mehdy Farhang, Martin Isaksson, Johan Wänman, Richard Löfvenberg, Sead Crnalic","doi":"10.2340/1651-226X.2024.40977","DOIUrl":"10.2340/1651-226X.2024.40977","url":null,"abstract":"Background and purpose: Pathologic and impending fractures occur in patients with advanced metastatic disease and necessitate surgical interventions with high risk of complications. The aim of this study was to analyze the efficacy of combined treatment with denosumab and radiotherapy as an alternative to surgery in treating bone metastases of the pelvis and extremities.Methods: This retrospective cohort study included 38 patients with impending and pathologic fractures due to carcinoma metastases who received monthly injections of denosumab (120 mg/dose) and radiotherapy. Twenty-three patients received denosumab and single-dose radiotherapy of 8 Gy, and 15 patients received denosumab and fractionated radiotherapy. We assessed pain, radiographic signs of fracture healing, survival and complications.Results: Of the 38 patients 36 experienced pain reduction. Callus formation was observed in 11/17 patients with pathologic fractures, and increased mineralization was found in 12/21 patients with impending fractures. In 23/38 patients, we found both pain reduction and callus formation or increased mineralization. There were no statistically significant differences in treatment outcomes between the patients who received denosumab and single-dose radiotherapy and those who received denosumab and fractionated radiotherapy. The survival rates at 30 days and 1 year were 95% and 56%, respectively.Interpretation: Combined treatment with denosumab and radiotherapy may reduce pain and promote bone healing in patients with metastatic impending and pathologic fractures. In this combined treatment, the effect of single-dose radiotherapy appears to be comparable to that of fractionated regimens.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"932-938"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11626079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adherence to adjuvant endocrine therapy after breast cancer in Sweden - a nationwide cohort study in 1-, 3- and 5-year survivors with a focus on regional differences. 瑞典乳腺癌术后坚持辅助内分泌治疗的情况--一项针对 1 年、3 年和 5 年存活者的全国性队列研究，重点关注地区差异。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-11-24 DOI: 10.2340/1651-226X.2024.40575

Anna De Jong, Anna Von Wachenfeldt, Lennarth Nyström, Anne Andersson

{"title":"Adherence to adjuvant endocrine therapy after breast cancer in Sweden - a nationwide cohort study in 1-, 3- and 5-year survivors with a focus on regional differences.","authors":"Anna De Jong, Anna Von Wachenfeldt, Lennarth Nyström, Anne Andersson","doi":"10.2340/1651-226X.2024.40575","DOIUrl":"10.2340/1651-226X.2024.40575","url":null,"abstract":"Background and purpose: Adjuvant endocrine treatment (AET) is crucial in early oestrogen receptor (ER)-positive breast cancer (BC), providing reduced recurrence rate and increased overall survival. The aim of this study was to estimate AET adherence rates by age at diagnosis and region in Sweden.Patients and methods: In total, 10,422 women diagnosed with ER-positive BC in 2008-2010 were identified in the Swedish National BC Registry. Information on prescriptions and dispensation of AET was gathered through record linkage to the Swedish Prescription Registry. 1, 3- and 5-year medication possession ratios (MPRs) were calculated. Good adherence was set as MPR ≥ 80%.Results: The 1-, 3- and 5-year AET age-adjusted adherence rates were 94.4, 87.6 and 81.6%, respectively. The 1-, 3- and 5- year adherence rate was significantly highest in the South region (96.2, 90.5 and 86.2%). Regions with an oncologic clinic had higher adherence rate than regions without, 82.8% versus 75.5% at 5-year FU. Women at age 40-64 years (95.6, 89.9 and 84.1%) and 65-74 years at diagnosis (95.7, 89.5 and 84.6%) had significantly higher adherence rate than women ≥ 75 years at diagnosis (89.1, 79.2 and 68.3%).Interpretations: Despite guidelines being national, there were significant differences in adherence between regions in Sweden. As the largest differences were between age groups invited and not invited to mammography screening intervention should focus on women < 40 and ≥ 75 years at diagnosis. Further studies are needed to find strategies to increase overall adherence to AET in early BC.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"901-908"},"PeriodicalIF":2.7,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11609876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142708508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MELACARE Nurse-led follow-up after early-stage melanoma: protocol and feasibility. MELACARE 早期黑色素瘤术后护士主导的随访：方案和可行性。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-11-24 DOI: 10.2340/1651-226X.2024.41037

Sara M Hansen, Christoffer Johansen, Magnus P B Obinah, Nadine A Kasparian, Peter Genter, Pernille E Bidstrup, Lisbet R Hölmich

{"title":"MELACARE Nurse-led follow-up after early-stage melanoma: protocol and feasibility.","authors":"Sara M Hansen, Christoffer Johansen, Magnus P B Obinah, Nadine A Kasparian, Peter Genter, Pernille E Bidstrup, Lisbet R Hölmich","doi":"10.2340/1651-226X.2024.41037","DOIUrl":"10.2340/1651-226X.2024.41037","url":null,"abstract":"Background and purpose: We developed the Melacare nurse-led intervention, which combines education in skin self-examination as a resource-conscious approach to detecting recurrence and management of fear of cancer recurrence in patients treated for melanoma. This publication presents the Melacare study protocol and evaluates the feasibility and acceptability of Melacare prior to a larger randomised controlled trial.Material and methods: Feasibility and acceptability of Melacare were evaluated in an intervention-only feasibility study, in which patients attended two nurse-led intervention sessions coupled with an educational booklet. Participants completed patient-reported outcome (PRO) questionnaires at baseline and before each session. After the intervention, participants completed a study-specific feedback questionnaire. Feasibility was evaluated in terms of recruitment, adherence, and attendance. Self-reported outcomes from the study-specific questionnaire on intervention effects were also collected. Results of the feasibility study: Fourteen patients (nine stage IA, five stage IB melanoma) participated. Attendance and recruitment rates were 100%, all participants completed the baseline and PRO questionnaires, and 100% read at least half of the educational booklet. In terms of intervention effects, all patients reported improved knowledge of performing skin self-examination and coping with the fear of cancer recurrence.Interpretation: Results indicate that the Melacare nurse-led intervention is highly feasible and acceptable for use with patients treated for early-stage melanoma. Prior to clinical trial commencement, minor refinements include changing the method of recruiting by telephone and offering.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"909-914"},"PeriodicalIF":2.7,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11609874/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142708519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aggressive end-of-life care in patients with gastrointestinal cancers - a nationwide study from Denmark. 胃肠道癌症患者的积极临终关怀--一项来自丹麦的全国性研究。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-11-24 DOI: 10.2340/1651-226X.2024.41008

Stine Gerhardt, Kirstine Skov Benthien, Suzanne Herling, Marie Villumsen, Peter-Martin Karup

{"title":"Aggressive end-of-life care in patients with gastrointestinal cancers - a nationwide study from Denmark.","authors":"Stine Gerhardt, Kirstine Skov Benthien, Suzanne Herling, Marie Villumsen, Peter-Martin Karup","doi":"10.2340/1651-226X.2024.41008","DOIUrl":"10.2340/1651-226X.2024.41008","url":null,"abstract":"Background: Knowledge of determinants of aggressive end-of-life care is crucial to organizing effective palliative care for patients with gastrointestinal (GI) cancer.Purpose: This study aims to investigate the determinants of aggressive end-of-life care in patients with GI cancer.Methods: A national register-based cohort study using data from the Danish Register on Causes of Death, the Danish National Patient Register, and the Danish Palliative Database was the method of study employed.Participants/setting: All Danish patients who died from GI cancers from 2010 to 2020 comprised the study setting.Results: There were 43,969 patients with GI cancers in the cohort, of whom 62% were hospitalized in the last 30 days of life, 41% of patients died in the hospital, 10% had surgery, 39% were subjected to a radiological examination during the last 30 days of life and 3% had antineoplastic treatment during the last 14 days of life. Among all types of GI cancers, pancreatic cancer was significantly associated with all outcomes of aggressive end-of-life care except surgery. Patients in specialized palliative care (SPC) had lower odds of receiving aggressive end-of-life care and dying in the hospital. We found that patients with comorbidity and those who were divorced had higher odds of being hospitalized at the end of life and dying in the hospital.Interpretation: Aggressive end-of-life care is associated with disease factors and socio-demographics. The potential to reduce aggressive end-of-life care is considerable in patients with GI cancer, as demonstrated by the impact of SPC. However, we need to address the needs of patients with GI cancer who do not receive SPC.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"915-923"},"PeriodicalIF":2.7,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11609878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142708526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Proportion and characteristics of screen-detected and non-screen-detected colo-rectal cancers in Germany. 德国筛查出和未筛查出结肠直肠癌的比例和特征。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-11-24 DOI: 10.2340/1651-226X.2024.40234

Michel Hornschuch, Sarina Schwarz, Ulrike Haug

{"title":"Proportion and characteristics of screen-detected and non-screen-detected colo-rectal cancers in Germany.","authors":"Michel Hornschuch, Sarina Schwarz, Ulrike Haug","doi":"10.2340/1651-226X.2024.40234","DOIUrl":"10.2340/1651-226X.2024.40234","url":null,"abstract":"Background: Germany has a long-standing colorectal cancer (CRC) screening offer. We aimed to quantify and characterize screen-detected colorectal cancers (sdCRCs) in Germany.Methods: We conducted a cross-sectional study based on a healthcare database covering ~20% of the German population; we included CRC patients aged ≥ 55 years diagnosed in 2010-2018. Patients with a screening colonoscopy or a fecal occult blood test followed by colonoscopy within 180 days before diagnosis were classified as sdCRCs and compared to non-sdCRCs regarding age, stage and comorbidities.Results: In 2018, 25% of male and 22% of female CRC patients were screen-detected. Regarding characteristics of all included CRC cases (N = 82,538), sdCRC patients were younger than non-sdCRCs (average difference men / women: 2.6 / 4.4 years). The proportion of advanced CRC among sdCRCs and non-sdCRCs, respectively, was 33 and 42% in women (men: 36 and 45%). Severe comorbidities were more prevalent in non-sdCRCs compared to sdCRCs (e.g. in male / female patients aged 65-74: 35% vs. 27% / 26% vs. 19%). Prevalences of hypertension and obesity were similar in both groups.Interpretation: Our study suggests that about one fourth of CRCs in Germany are screen-detected. Among patients with non-sdCRC, not only advanced stage but also severe comorbidity was more common than in sdCRCs.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"924-931"},"PeriodicalIF":2.7,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11609877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142708532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0